ArticleEndocrine2025
Impact of age, obesity, testosterone, and patient education on the prevalence, incidence, and remission of sexual dysfunction in women with newly diagnosed and uncomplicated type 2 diabetes.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFemale sexual dysfunction (FSD) is a common but underexplored complication in women with type 2 diabetes (T2D). This longitudinal study assessed the prevalence, incidence, and remission of FSD in women with newly diagnosed, uncomplicated T2D, and identified associated predictors.
methodsWe enrolled 388 women (mean follow-up: 60.5 ± 20.4 months) from a larger cohort of 937 newly diagnosed T2D patients. FSD was assessed using the Female Sexual Function Index (FSFI), with a cut-off score < 26.55 defining FSD. Baseline and follow-up evaluations included anthropometric, metabolic, hormonal, and therapeutic parameters, including participation in therapeutic patient education (TPE). Multivariate logistic regression was used to identify predictors of FSD prevalence, incidence, and remission.
resultsAt baseline, FSD prevalence was 42.8%. During follow-up, 30.2% of initially unaffected women developed FSD (6.0% annual incidence), while 28.9% of women with baseline FSD achieved remission (5.8% annual remission). Baseline FSD was independently associated with age > 50 years and BMI > 30 kg/m². FSD incidence was inversely associated with total testosterone > 28.5 ng/dL and TPE. FSD remission was predicted by TPE participation and a ≥ 3-point BMI reduction. At follow-up, FSD prevalence rose to 47.7%.
conclusionFSD is common in early-stage T2D, with identifiable predictors of both its onset and remission. Age, obesity, testosterone levels, and TPE significantly influence FSD dynamics. These findings support early FSD screening and integration of sexual health into comprehensive diabetes care.
Indexed as
Identifiers
40705157What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.